Given your lack of any realistic knowledge of the basic finances of injectables I highly doubt you have 25 years experience in the toxin industry.
Also, you are now completely pulling stuff out of your a$$ saying that the peptide application improves skin tone.
The major problem here is a lack of efficacy of the real world product. At double the [unit]dose the real world duration (time between treatment) we are seeing in patients is around 4 months, occasionally 4.5 months. Nowhere near the 6 months originally advertised/marketed.The major problem is that with equivalent dosing (1:1 Botox Units or 1:3 dysport units) we are seeing 2-3 months duration (time between treatments) with Daxxify, which is actually shorter than with Botox and Dysport. So while the cost may be slightly less at equivalent dosing (with the caveat that it is only slightly less than I pay for Dysport, my toxin of choice) if duration is equivalent to Xeomin/Jeaveau there is absolutely no incentive to use their products from a price OR efficacy standpoint. Add the increased injection pain (which patients DO notice) and you have a product that really doesn't provide a significant benefit, for injector or patient, versus any other toxin currently available.
Lastly, a key fact that everyone overlooks is that over a decade ago Allergan (before it became the devil company in our industry) looked at adding stabilizing peptides to onabotulinum (Botox) with the idea that it would increase duration. They found that while it increased duration slightly it was not a significant enough increase in duration to proceed with wide scale trials.
RHA fillers are mediocre and the line (at least in the US) is very limited in scope.
